Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

Frontiers in Immunology

Ganesan Ramamoorthi¹  Amrita Basu¹  Amber Beyer¹  Gabriella Albert¹  Corey Gallen¹  Colin Snyder¹  Krithika Kodumudi²  Gary Koski²  Brian J. Czerniecki³  Mary L. Disis⁵ 

[1] Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States;Department of Biological Sciences, Kent State University, Kent, OH, United States;Department of Breast Cancer Program, Moffitt Cancer Center, Tampa, FL, United States;Department of Oncological Sciences, University of South Florida, Tampa, FL, United States;UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, United States;

关键词: T helper;    CD4;    neoantigen;    tumor associated antigen;    immunotherapy;   

DOI  :  10.3389/fimmu.2021.669474

来源: DOAJ

【 摘 要 】

Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells in the tumor which are critical for activation of anti-tumor response either directly by themselves or by stimulating cytotoxic T cell activity. However, presence of immunosuppressive pro-tumorigenic TH subsets in the tumor milieu further contributes to the complexity of regulation of TH cell-mediated immune response. In this review, we present an overview of the multifaceted positive and negative effects of TH cells, with an emphasis on regulation of different TH cell subtypes by various immune cells, and how a delicate balance of contradictory signals can influence overall success of cancer immunotherapy. We focus on the regulatory network that encompasses dendritic cell-induced activation of CD4+ TH1 cells and subsequent priming of CD8+ cytotoxic T cells, along with intersecting anti-inflammatory and pro-tumorigenic TH2 cell activity. We further discuss how other tumor infiltrating immune cells such as immunostimulatory TH9 and Tfh cells, immunosuppressive Treg cells, and the duality of TH17 function contribute to tip the balance of anti- vs pro-tumorigenic TH responses in the tumor. We highlight the developing knowledge of CD4+ TH1 immune response against neoantigens/oncodrivers, impact of current immunotherapy strategies on CD4+ TH1 immunity, and how opposing action of TH cell subtypes can be explored further to amplify immunotherapy success in patients. Understanding the nuances of CD4+ TH cells regulation and the molecular framework undergirding the balancing act between anti- vs pro-tumorigenic TH subtypes is critical for rational designing of immunotherapies that can bypass therapeutic escape to maximize the potential of immunotherapy.

【 授权许可】

Unknown